A1-techdoc | Maintain technical documentation (medical device file and design files) that evidences regulatory compliance, keep it current, and for Australia meet the minimum Essential Principl | 0 |
A2-sterile | Control every process contributing to sterility through the QMS, with validated and revalidated processes, routine monitoring, batch records, designated lot release and controlled | 0 |
A3-A5 | Annex 3 reporting timeframes, Annex 4 Japan QMS Ordinance tables, Annex 5 acceptable exclusions, and the MDO eligibility pilot (MDSAP AU P0038.002) | 0 |
C1-T1 | Plan, document and maintain the QMS with a risk-based approach to process control, manage QMS changes and keep a quality manual | 0 |
C1-T10 | Distribute or offer devices only into markets where they hold the required marketing authorization, and license and label private-label devices for Canada correctly | 0 |
C1-T11 | Top management demonstrates commitment to an effective QMS and communicates its effectiveness, as judged across management, measurement and improvement, design, production and purc | 0 |
C1-T2 | Appoint and document a management representative responsible for QMS effectiveness, reporting to top management and promoting regulatory awareness | 0 |
C1-T3 | Set a quality policy and measurable quality objectives at relevant functions and levels, consistent with the policy, and act to achieve them | 0 |
C1-T4 | Define the organisational structure, responsibilities and authorities, and provide the people, infrastructure, competence and training needed to design and make devices as planned | 0 |
C1-T5 | Document the extent of outsourcing and the controls over outsourced processes, keep the supplier list current, and divide regulatory duties correctly with sponsors, importers and c | 0 |
C1-T6 | Determine competence needs for work affecting quality, close gaps, check effectiveness in proportion to risk, keep competence records and qualify consultants | 0 |
C1-T7 | Top management commits to and owns risk management planning across the product life cycle, with documented methods, acceptability criteria and post-market updating of risk files | 0 |
C1-T8 | Control documents and records of internal and external origin, and keep records and an obsolete copy of documents for at least the device lifetime (minimum two years) or the longer | 0 |
C1-T9 | Conduct documented management reviews at planned intervals covering the suitability and effectiveness of the policy, objectives and QMS against all regulatory requirements | 0 |
C2-T1 | Register facilities and list or license devices as each jurisdiction requires, and (for Australia) compile and maintain the manufacturer's Declaration of Conformity | 0 |
C2-T2 | Hold the marketing clearance or approval each jurisdiction requires before commercial distribution (ANVISA registration or notification, Canadian licence, Japanese approval, FDA 51 | 0 |
C2-T3-AU | Identify changes needing regulatory notification and, for Australia, notify the MDSAP auditing organisation (and the TGA for conformity assessment certificate holders) before subst | 0 |
C2-T3-BR-CA-JP | Submit significant changes to ANVISA, Health Canada licence amendments and annual statements, and Japanese change applications through the marketing authorization holder | 0 |
C2-T3-US | For the United States, update registration and listing, file new 510(k)s or PMA supplements for significant changes, and keep changes within any agreed predetermined change control | 0 |
C3-T1 | Establish documented measurement, analysis and improvement procedures covering monitoring of product conformity, early-warning feedback, CAPA and dissemination of quality problem i | 0 |
C3-T10 | Run planned internal audits under a documented procedure with trained, independent auditors, and follow up findings with corrections, corrective actions and verification | 0 |
C3-T11 | Feed nonconforming product, QMS nonconformity, correction, corrective and preventive action information into management review | 0 |
C3-T12 | Gather and evaluate post-production experience, including complaints and post-market surveillance, feed it into improvement and risk management, and (for Australia) pass serious pr | 0 |
C3-T12-BR-US | Keep complaint handling procedures and records that meet ANVISA and FDA rules: a designated unit, documented decisions not to investigate, mandatory investigation of failures and r | 0 |
C3-T12-CA | For Canada, keep problem and complaint records, run effective investigation and recall procedures, prepare periodic summary reports with critical benefit-risk analysis and notify t | 0 |
C3-T12-CYBER | For devices with software or programmable logic, collect cybersecurity feedback (vulnerability reports, incidents, threat intelligence) after release and feed it into risk manageme | 0 |
C3-T13 | Exchange relevant information with external organisations whose activities contributed to a complaint, and keep records of it | 0 |
C3-T14-T15 | Evaluate every complaint for adverse event reportability and every quality problem in distributed product for an advisory notice, under documented procedures with recorded rational | 0 |
C3-T2 | Identify and analyse all relevant quality data sources under a documented procedure, using valid statistical methods where appropriate | 0 |
C3-T3-T4 | Investigate the root causes of nonconformities and potential nonconformities where possible, with depth proportionate to the risk | 0 |
C3-T5 | Determine, implement, document and verify corrections, corrective actions and preventive actions in proportion to risk, without adverse effect on finished devices | 0 |
C3-T6-T7 | Evaluate new hazards and risks from CAPA-driven design or process changes, revalidate processes where needed, and notify regulators, auditing organisations or MAHs of significant o | 0 |
C3-T8-T9 | Identify and control nonconforming product to prevent use or delivery, justify and record dispositions, notify responsible external parties, and act in proportion to risk when nonc | 0 |
C4-T1-AU | Australia: report adverse events and near adverse events to the TGA or the Australian sponsor as soon as practicable through the post-marketing system | 0 |
C4-T1-BR | Brazil: run an integrated post-market surveillance system with a designated responsible professional, record and investigate complaints, and notify ANVISA of adverse events, techni | 0 |
C4-T1-CA | Canada: make preliminary incident reports within 10 days (death or serious deterioration) or 30 days (could recur and cause it), follow with final reports, and report foreign serio | 0 |
C4-T1-JP | Japan: as a Registered Manufacturing Site, pass serious and specified events, foreign safety actions and study findings to the marketing authorization holder promptly | 0 |
C4-T1-US | United States: maintain written MDR procedures and event files, report deaths, serious injuries and reportable malfunctions within 30 calendar days, 5-day reports where remedial ac | 0 |
C4-T2-AU | Australia: tell the TGA or the sponsor as soon as practicable when the manufacturer proposes to recall devices distributed in Australia, with the technical or medical reasons | 0 |
C4-T2-BR | Brazil: define when field actions are needed, keep records of all field actions, carry them out on evidence of non-compliance or on ANVISA's demand, and notify ANVISA within the se | 0 |
C4-T2-CA | Canada: give Health Canada recall information within 24 hours of the decision, a full written section 64 report within three business days, and a results report after completion | 0 |
C4-T2-JP | Japan: as a Registered Manufacturing Site, maintain effective communication with the marketing authorization holder on advisory notices so the holder can report them | 0 |
C4-T2-US | United States: report corrections and removals made to reduce a risk to health or remedy a violation within 10 working days, with device identifiers, and keep records of unreported | 0 |
C5-T1 | Identify which devices are subject to design and development controls in each jurisdiction and maintain the technical documentation evidence they require | 0 |
C5-T10-T11 | Validate the design for the intended use with testing scaled to risk, and perform the clinical evaluation or safety and performance evaluation each jurisdiction requires | 0 |
C5-T12 | Develop device software under design controls and risk management | 0 |
C5-T12-US | United States: for cyber devices cleared or approved after 29 March 2023, maintain a postmarket vulnerability plan with coordinated disclosure, cybersecure design and update proces | 0 |
C5-T13 | Control design changes (verify or validate and approve before implementation, assess new risks), notify regulators or the MAH where required, and assign new UDI-DIs for new version | 0 |
C5-T14-T15 | Hold design reviews at planned stages with the right functions and specialists, and review design changes for their effect on product already made and delivered | 0 |
C5-T16 | Transfer the design correctly to production, releasing it only after authorised review of the complete design history | 0 |
C5-T3-T4 | Plan and control each design and development project, with stages, reviews, verification, validation, transfer, responsibilities and interfaces, under established procedures | 0 |
C5-T5-T6 | Establish, review and approve complete, unambiguous, non-conflicting design inputs covering function, performance, safety, intended use, regulations (including Essential Principles | 0 |
C5-T7 | Make design outputs traceable to and satisfy inputs, identify the outputs essential for proper functioning, and verify the design | 0 |
C5-T8-T9 | Apply risk management throughout design with defined acceptability criteria, evaluate and communicate residual risk, and confirm through verification or validation that risk contro | 0 |
C6-T1 | Plan product realization with the controls, controlled conditions and risk management needed to meet intended use and regulatory requirements, consistent with the rest of the QMS a | 0 |
C6-T1-UDI | Determine UDI applicability and implement UDI allocation, carriers and data management for Australia (TGA-recognised issuing agency) and the United States (FDA-accredited agency an | 0 |
C6-T10-T11 | Monitor and measure product conformity to a risk-based extent, and operate production within specified limits with production risk controls implemented, monitored and evaluated | 0 |
C6-T12 | Ensure production personnel are competent to carry out and maintain the processes as the organisation requires | 0 |
C6-T13-T14 | Identify, calibrate, adjust and protect monitoring and measuring equipment, and assess and record the validity of earlier results and act on affected product when equipment is foun | 0 |
C6-T15 | Validate software used to control production and service processes, in production equipment or in the QMS for its intended use | 0 |
C6-T16 | Keep a medical device file for each device type with specifications, process, QA, traceability, labelling and packaging and installation and servicing requirements, set traceabilit | 0 |
C6-T17 | Keep a verified, approved batch production record showing quantities made and released, manufacture to the device file and met release requirements, with inspected and controlled l | 0 |
C6-T18 | For implantable, life-supporting or life-sustaining devices, keep traceability of components, materials and environment conditions and inspection personnel, require distributors to | 0 |
C6-T19-T20 | Identify product status so only product that passed inspection is dispatched, used or installed, and identify, verify, protect and safeguard customer property including patient and | 0 |
C6-T21 | Carry out and document acceptance activities for every incoming item and service, to an extent matched to the device risk, with statistically valid sampling for Brazil | 0 |
C6-T22-T23 | Identify, control and dispose of nonconforming product according to risk, and rework only under approved procedures that assess adverse effects, document results and re-verify the | 0 |
C6-T24 | Preserve product conformity through processing, storage and transport, including identification, handling, packaging, protection, limited shelf life and special storage conditions | 0 |
C6-T25 | Review customer requirements before committing to supply, and keep the distribution records regulators require (consignee, product, quantity, date and control numbers; Canadian ret | 0 |
C6-T26-T27 | Record installation and its verification, perform and document servicing to defined procedures, analyse service records as quality data, and meet ANVISA and FDA service record cont | 0 |
C6-T28 | Apply risk control and mitigation measures to transport, installation and servicing in line with the risk management practice | 0 |
C6-T3 | Run production and service under controlled conditions: product information, procedures and workmanship criteria, suitable equipment, monitoring devices, process and product monito | 0 |
C6-T4 | Set documented product cleanliness requirements (including before sterilisation and for non-sterile supply) and removal of process agents, with pest control and housekeeping for Br | 0 |
C6-T5-T6 | Define and maintain the infrastructure and work environment needed for conformity, including equipment maintenance, personnel health and clothing, environmental monitoring, special | 0 |
C6-T7-T8 | Identify the processes (including outsourced ones) that need validation and validate them under documented procedures, with revalidation after changes and methods reflecting the st | 0 |
C6-T9 | Validate and periodically revalidate sterilisation and sterile barrier processes, manufacture sterile devices under controlled conditions and keep batch-traceable sterilisation rec | 0 |
C7-T1-T3 | Plan purchasing (what to buy and outsource, requirements, records, resources, acceptance and risk management) and document procedures ensuring purchased product meets requirements | 0 |
C7-T10-T11 | Verify purchased product to a risk-appropriate combination of supplier controls, purchase requirements and acceptance, keep verification records, hold material until verified (Braz | 0 |
C7-T4-T5 | Set documented, risk-based criteria for selecting, evaluating and re-evaluating suppliers, select suppliers on their ability to meet requirements, keep evaluation records and quali | 0 |
C7-T6-T7 | Monitor supplier performance, maintain effective controls so requirements continue to be met, and re-evaluate suppliers at intervals matched to the significance of their product | 0 |
C7-T8-T9 | Ensure purchasing information is adequate and documented before release to the supplier, including product, process, personnel and QMS requirements, risk controls, traceability and | 0 |
cycle | MDSAP audit cycle: initial (stage 1 and 2), surveillance, recertification, special, unannounced and regulator audits | 0 |
overview | What MDSAP is, the process-based audit sequence and how tasks cite requirements | 0 |
selection | Auditor sample selection tasks (design project, production process, supplier file) | 0 |